Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feitejinan
- Development stage
- Unknown
- Lead developer
- Chengdu Antech Bioscience
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Feitejinan** is Fosun Adgenvax's investigational 13-valent pneumococcal conjugate vaccine for active immunization against pneumococcal disease. It is designed to induce serotype-specific anti-capsular-polysaccharide antibodies against *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, promoting opsonophagocytic clearance and protection from invasive and noninvasive pneumococcal infections. The vaccine is a multivalent conjugate product reported to use CRM197 and tetanus-toxoid carrier proteins, and it has been evaluated in Phase III infant studies, including long-term immunogenicity persistence after primary and booster vaccination. ([health.baidu.com](https://health.baidu.com/m/detail/ar_10296028746173522069))
- Other names
- 13-valent pneumococcal conjugate vaccine (Fosun Adgenvax)13-valent pneumococcal conjugate vaccine (multivalent conjugate)13价肺炎球菌结合疫苗（多价结合体）FeitejinanPCV13 (Fosun Adgenvax)沸特金安
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)BCR-SpCPS (B-cell receptor specific for Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Feitejinan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Feitejinan.